HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

922.842

-7.905-0.85%

Number of Gainers:4

Number of Losers:8

Number of Flat:1

PE:- -

High:933.426

Open:931.184

Low:920.261

Close:930.747

Volume:70.05M

Turnover:515.89M

Market Cap:151.95B

Float Cap:113.75B

Loading ...

Ruili Aesthetics Reports Interim Profit Turnaround with Net Income of RMB 4.1 Million

Raily Aesthetic Medicine FY26 Interim Profit Turns to RMB 3.51 Million; Revenue Rises 35.7% to RMB 114.78 Million

Fosun Pharma Allocates 725,100 A-Share Options to Employees

Miricor Seeks Shareholder Approval for New Share Option Scheme with 10% Cap

Miricor Enterprises Announces Extraordinary General Meeting

HAOHAI BIOTEC Allocates HK$1.05 Million to Buy Back 63,800 Shares on August 28

Shanghai Fosun Pharmaceutical's GR1803 Injection Gets Conditional Approval in China

MT Newswires Live

Sihuan Pharmaceutical (SEHK:460) Stock Price Lags Profit Recovery as Valuation Stretches

Simply Wall St.

Fosun Pharma Secures Conditional NMPA Approval for GR1803 Injection

Shanghai Fosun Pharma - Recently, Marketing Registration Application for Gr1803 Injection Has Been Approved with Conditions by Nmpa China

THOMSON REUTERS

MODERN DENTAL Reports Interim Profit of HK$374 Million, Up 31.2% Year-on-Year

Modern Dental H1 FY26 Net Profit Climbs 30.8% to Hk$377.57 Million; Revenue Rises 10.8% to Hk$2.03 Billion

Modern Dental Group H1 Revenue HKD 2,032.5 Million

THOMSON REUTERS

Modern Dental Group Interim Dividend of Hk14.0 Cents Per Share

THOMSON REUTERS

Sihuan Pharma Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 0.81

Fosun Pharma Completes HK$3.587 Million Share Buyback on August 27

Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand

China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%

Sihuan Pharma FY26 H1 Profit Attributable to Owners Rises 119% to RMB 224.7 Million; Revenue Increases 1.3% to RMB 1.16 Billion

Sihuan Pharmaceutical Files Board, Committee Roles and Disclosure-Responsible Management List

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":922.8416,"timestamp":1787904511585,"preClose":930.747,"halted":0,"volume":70046465,"delay":0,"changeRate":-0.008494,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-7.905396,"latestTime":"08-28 16:00:00","open":931.18365,"high":933.4258,"low":920.2605,"amount":515888474,"amplitude":0.014145,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"pbRate":1.180847,"peRate":10.919282,"turnoverRate":0.003397,"increases":3,"decrements":9,"flats":1,"marketCap":151953186144,"floatMarketCap":113749015904},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":933.4258,"amplitude":0.014145,"preClose":930.747,"low":920.2605,"pbRate":"1.180847","latestPrice":922.8416,"volume":70046465,"delay":0,"open":931.18365,"prevYearClose":1094.978,"prevWeekClose":922.842,"prevMonthClose":920.614,"prevQuarterClose":846.145,"fiveDayClose":957.756,"twentyDayClose":920.614,"sixtyDayClose":869.242,"secType":"PLATE","market":"HK","turnoverRate":0.003397,"peRate":10.919282,"marketCap":151953186144,"floatMarketCap":113749015904,"timestamp":1787904511585,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":8,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1163059918","title":"Ruili Aesthetics Reports Interim Profit Turnaround with Net Income of RMB 4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1163059918","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163059918?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:24","pubTimestamp":1787927059,"startTime":"0","endTime":"0","summary":"RAILY AESMED (02135) has unveiled its interim results for the six months ended June 30, 2026, showcasing a positive financial shift. The company achieved a group revenue of RMB 115 million, marking a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662093761","title":"Raily Aesthetic Medicine FY26 Interim Profit Turns to RMB 3.51 Million; Revenue Rises 35.7% to RMB 114.78 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662093761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662093761?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:01","pubTimestamp":1787922075,"startTime":"0","endTime":"0","summary":"Raily Aesthetic Medicine FY26 interim profit turns to RMB 3.51 million; revenue rises 35.7% to RMB 114.78 millionRaily Aesthetic Medicine returned to profit, posting RMB 3.51 million profit, versus a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL8XSQb6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","02135","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184432934","title":"Fosun Pharma Allocates 725,100 A-Share Options to Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=1184432934","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184432934?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:00","pubTimestamp":1787914813,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) has announced a new round of equity incentives, granting a total of 725,100 A-share options to 100 eligible recipients.According to the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0188","600196","BK0239","BK1593","02846","03188","02196","83188","BK0028","03130","07233","BK0012","BK0196","BK0096","BK1191","BK0060","02827","159982","BK1515","BK1147","BK0175","83130","399300","BK0187","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662506479","title":"Miricor Seeks Shareholder Approval for New Share Option Scheme with 10% Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2662506479","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662506479?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:53","pubTimestamp":1787914436,"startTime":"0","endTime":"0","summary":"Miricor seeks shareholder approval for new share option scheme with 10% capMiricor scheduled a Sept. 18, 2026 EGM to vote on adopting a new share option scheme.The existing share option scheme, adopte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL7rK8TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1215","01827","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064799","title":"Miricor Enterprises Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662064799?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:53","pubTimestamp":1787914429,"startTime":"0","endTime":"0","summary":"Miricor Enterprises announces extraordinary general meetingMiricor Enterprises will hold an extraordinary general meeting in Hong Kong on Sept. 18, 2026.Shareholders will vote on terminating the exist","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL8JRl5B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01827","BK1593","BK1215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137603738","title":"HAOHAI BIOTEC Allocates HK$1.05 Million to Buy Back 63,800 Shares on August 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1137603738","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137603738?lang=en_us&edition=fundamental","pubTime":"2026-08-28 17:40","pubTimestamp":1787910020,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) has disclosed a share buyback transaction.On August 28, 2026, the company spent approximately HK$1.053 million to repurchase 63,800 of its own shares.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056779","title":"Shanghai Fosun Pharmaceutical's GR1803 Injection Gets Conditional Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056779","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662056779?lang=en_us&edition=fundamental","pubTime":"2026-08-28 13:20","pubTimestamp":1787894451,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  GR1803 injection received conditional approval from China's National Medical Products Administration as a multiple myeloma treatment, according to a Friday disclosure on the Shanghai bourse.The drug, which has the generic name veritumab injection, is for adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of therapy, including a proteasome inhibitor and an anti-CD38 monoclonal antibody.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK1593","BK0187","BK0012","600196","BK0060","BK0188","02196","BK0175","BK1515","BK0028","BK0239","BK0183","BK0196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084715","title":"Sihuan Pharmaceutical (SEHK:460) Stock Price Lags Profit Recovery as Valuation Stretches","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084715","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084715?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:24","pubTimestamp":1787840647,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group entered these results following a period of weak share price performance, with the stock down over the past week, month and quarter, yet trading on a rich P/E of 21x. That is a set up for emotional trading. The headline from this half year is simple. Profitability has firmed up, with basic earnings per share at C¥0.0249 on revenue of C¥1,161.2m. The tug of war now is between investors who are concerned about the valuation strain and those who see a company...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/sihuan-pharmaceutical-sehk460-stock-price-lags-profit-recove","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/sihuan-pharmaceutical-sehk460-stock-price-lags-profit-recove","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","BK1600","BK1593","00460","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199001247","title":"Fosun Pharma Secures Conditional NMPA Approval for GR1803 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1199001247","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199001247?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:20","pubTimestamp":1787829620,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (H-share ticker: 02196) announced that its controlling subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd. (\"Yaoyou Pharma\"), has obtained...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0175","BK0188","BK1593","BK1191","BK0060","BK1515","600196","02196","BK0028","BK0096","BK0196","BK0012","BK0183","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662709438","title":"Shanghai Fosun Pharma - Recently, Marketing Registration Application for Gr1803 Injection Has Been Approved with Conditions by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662709438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662709438?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:06","pubTimestamp":1787828777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK0183","BK0239","BK0187","BK0012","BK0196","600196","BK0188","BK0096","BK1515","BK0175","BK1593","BK0028","BK0060","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127873015","title":"MODERN DENTAL Reports Interim Profit of HK$374 Million, Up 31.2% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1127873015","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127873015?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:56","pubTimestamp":1787828178,"startTime":"0","endTime":"0","summary":"MODERN DENTAL (03600) has announced its interim results for the six months ended June 30, 2026, posting a revenue of HK$2.032 billion, representing a year-on-year increase of 10.8%. Profit...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1100","03600","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061557","title":"Modern Dental H1 FY26 Net Profit Climbs 30.8% to Hk$377.57 Million; Revenue Rises 10.8% to Hk$2.03 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061557","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061557?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:47","pubTimestamp":1787827679,"startTime":"0","endTime":"0","summary":"Modern Dental H1 FY26 net profit climbs 30.8% to HK$377.57 million; revenue rises 10.8% to HK$2.03 billionModern Dental Group posted net profit of HK$377.57 million, up 30.8% from a year earlier.Reven","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL9WTFc5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03600","BK1593","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662870612","title":"Modern Dental Group H1 Revenue HKD 2,032.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662870612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662870612?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:47","pubTimestamp":1787827660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXND4KM6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1583","03600","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061207","title":"Modern Dental Group Interim Dividend of Hk14.0 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061207?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:47","pubTimestamp":1787827660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXND4KM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","03600","BK1593","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705289","title":"Sihuan Pharma Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 0.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705289","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705289?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:34","pubTimestamp":1787826855,"startTime":"0","endTime":"0","summary":"Sihuan Pharma files HKEX next-day return disclosing share repurchase at HKD 0.81Sihuan Pharmaceutical repurchased 10,000,000 ordinary shares on Aug. 27, holding all as treasury shares.Buyback price ra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL6cXYkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","00460","BK1191","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132782268","title":"Fosun Pharma Completes HK$3.587 Million Share Buyback on August 27","url":"https://stock-news.laohu8.com/highlight/detail?id=1132782268","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132782268?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:40","pubTimestamp":1787823619,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has announced that on August 27, 2026, it repurchased 217,000 shares of its stock for a total consideration of HK$3.587 million.The buyback transaction reflects the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0096","BK0196","600196","BK1593","BK0060","02196","BK0175","BK0183","BK0187","BK0188","BK1515","BK1191","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662717592","title":"Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717592","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662717592?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:54","pubTimestamp":1787752465,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical H1 revenue rises on nuclear medicine demandOverviewHong Kong-listed pharma group's H1 revenue rose 3.2% yr/yr to HK$6.39 blnNet income attributable to owners fell to HK$1.06 bln f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1593","BK1589","BK1515","00512","BK1600","03692","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715194","title":"China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715194","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715194?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:36","pubTimestamp":1787744170,"startTime":"0","endTime":"0","summary":"China's Zhongzhi Pharmaceutical H1 revenue falls 10%OverviewChina pharmaceutical maker's half-year revenue fell 10.3% yr/yrProfit attributable to owners rose 3.8% yr/yrGross profit and margin declined","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","BK1600","BK1606","03692","BK1515","BK1593","BK1191","03737","00460","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973617","title":"Sihuan Pharma FY26 H1 Profit Attributable to Owners Rises 119% to RMB 224.7 Million; Revenue Increases 1.3% to RMB 1.16 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973617","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662973617?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:08","pubTimestamp":1787738933,"startTime":"0","endTime":"0","summary":"Sihuan Pharma FY26 H1 profit attributable to owners rises 119% to RMB 224.7 million; revenue increases 1.3% to RMB 1.16 billionSihuan Pharmaceutical posted profit attributable to owners of RMB 224.7 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLc1wDYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1191","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794653","title":"Sihuan Pharmaceutical Files Board, Committee Roles and Disclosure-Responsible Management List","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794653","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662794653?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:38","pubTimestamp":1787737093,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical files board, committee roles and disclosure-responsible management listSihuan Pharmaceutical named Che Fengsheng as chairman; Guo Weicheng as vice chairman, chief executive; exec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1yGHl8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","BK1191","BK1515","00460"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}]}}